Boston Scientific Launches TAVR Device in Europe

Boston Scientific is set to make a significant impact in the European transcatheter aortic valve replacement (TAVR) market with the upcoming launch of its Acurate Prime system. Designed to cover 25% more of the market, this advancement could reshape the competitive landscape, currently dominated by Edwards Lifesciences and Medtronic.

Boston Scientific has strategically developed Acurate Prime to address aortic annulus diameters between 20.5 and 29 mm, surpassing the maximum coverage of its predecessor, Neo2. This enhancement positions the company to better meet the demands of a broader patient population. Despite fierce competition, Boston Scientific’s CEO, Michael Mahoney, remains optimistic about the new system’s potential, citing its design improvements and retained features from Neo2. These include low pacemaker and paravalvular leak rates, strong hemodynamic performance, and easy coronary access for future procedures.

With the launch of Acurate Prime in Europe imminent and plans to introduce it to the U.S. market underway, Boston Scientific is poised to expand its footprint in the TAVR space significantly. As the company navigates through clinical trial data and regulatory landscapes, it is clear that the new device holds promise for patients and the medtech industry alike—ushering in a new era of innovation and competitive dynamics.